Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from Genzyme on the shortage of Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta), which are used to treat patients with Gaucher disease and Fabry disease, respectively.
Important Safety Information - Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta)